NCT05681819View on ClinicalTrials.gov

Safety, Tolerability and Pharmacodynamics of SHR-1707 in Alzheimer's Disease Patients.

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 17, 2023

Primary Completion Date

May 18, 2024

Study Completion Date

July 18, 2025

Conditions
Alzheimer's Disease
Interventions
DRUG

SHR-1707

Multiple-ascending Dose

DRUG

SHR-1707 placebo

Multiple-ascending Dose

Trial Locations (1)

230001

The First Affiliated Hospital Of USTC, Hefei

All Listed Sponsors
lead

Shanghai Hengrui Pharmaceutical Co., Ltd.

INDUSTRY